Real-world outcomes and safety of inetetamab plus pyrotinib and chemotherapy in HER2-positive metastatic breast cancer: A multicenter retrospective study
Fan Wu, Cailing Lin, Zhiwu Lin, Qingmo Yang, Xiuping Wu, Biyin Chen, Nani Li, Ruxue Zhang, Xiufeng Wu, Weiwei Huang, Xinhua Chen, Yi Hong, Kan Chen, Jian Liu · 2026
Read Real-world outcomes and safety of inetetamab plus pyrotinib and chemotherapy in HER2-positive metastatic breast cancer: A multicenter retrospective study by Fan Wu, Cailing Lin, Zhiwu Lin, Qingmo Yang, Xiuping Wu, Biyin Chen, Nani Li, Ruxue Zhang, Xiufeng Wu, Weiwei Huang, Xinhua Chen, Yi Hong, Kan Chen, Jian Liu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13469565.txt.
Description
BackgroundInetetamab and pyrotinib have shown promising activity in HER2-positive metastatic breast cancer (MBC). However, real-world data on their combination with chemotherapy (IPyC) across different treatment lines remain limited.ObjectivesThis multicenter retrospective study aimed to describe the outcomes associated with a dual HER2-targeting strategy IPyC in HER2-positive MBC across treatment lines in real-world clinical practice.DesignMulticenter retrospective study.
Catalog record
| CREATOR | Fan Wu, Cailing Lin, Zhiwu Lin, Qingmo Yang, Xiuping Wu, Biyin Chen, Nani Li, Ruxue Zhang, Xiufeng Wu, Weiwei Huang, Xinhua Chen, Yi Hong, Kan Chen, Jian Liu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 43 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |